# Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

> **NCT00003439** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** recombinant interleukin-12

## Key facts

- **NCT ID:** NCT00003439
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2001-05
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003439, "Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00003439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*